

**Table 5. Summary of the relative potencies of the B9X.1.2, B9X14, B9X22 and B9X25 compared to the control compounds IFN-con1, IFN- $\alpha$ 2a, and IFN- $\alpha$ 2b in the HeLa EMCV antiviral assay**

Sample <sup>†</sup>	Mean log EC <sub>50</sub>	SD	<i>n</i>	Mean EC <sub>50</sub> , ng/ml	Fold over IFN- $\alpha$ 2b <sup>‡</sup>	Fold over IFN-con1 <sup>‡</sup>	<i>P</i> value sample vs. IFN-con1
B9X25 *	-2.21	0.338	13	0.00616	67	17	<0.0001
B9X14 *	-2.21	0.230	21	0.00617	67	17	<0.0001
B9.1.2 *	-2.04	0.263	16	0.00920	45	11	<0.0001
B9X22 *	-1.86	0.323	4	0.0139	30	7.5	<0.0001
IFN-con1	-0.981	0.385	21	0.104	4.0	1.0	<0.0001
IFN- $\alpha$ 2b *	-0.385	0.375	22	0.412	1.0	0.25	<0.0001
IFN- $\alpha$ 2a *	-0.326	0.387	22	0.472	0.87	0.22	<0.0001

The samples are listed in order of decreasing antiviral potency.

<sup>†</sup>The mean Log EC<sub>50</sub> values of those interferon samples marked with an asterisk are statistically different at the 95% confidence level from the mean Log EC<sub>50</sub> value of IFN-con1 in the HeLa EMCV assay based on a two-way ANOVA (sample and experiment) and Fisher's least significant difference post hoc test ( $\alpha = 0.05$ ). The Hill slopes and (SD) are: IFN- $\alpha$ 2b 0.83 (0.18), IFN-con1 0.88 (0.19), B9X14 1.55 (0.34), B9X25 1.49 (0.35).

<sup>‡</sup>Fold improvements were calculated as a ratio of mean EC<sub>50</sub> (ng/ml) values relative to IFN- $\alpha$ 2b and IFN-con1.